Search Results

Filter
  • 1-10 of  3,427 results for ""INFLIXIMAB""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept.

  • Authors : Gholami A; Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.; Biotechnology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Subjects: Adalimumab/Adalimumab/Adalimumab/*therapeutic use ; Arthritis, Rheumatoid/Arthritis, Rheumatoid/Arthritis, Rheumatoid/*drug therapy ; Biological Products/Biological Products/Biological Products/*therapeutic use

  • Source: BioMed research international [Biomed Res Int] 2021 Nov 28; Vol. 2021, pp. 4450162. Date of Electronic Publication: 2021 Nov 28 (Print Publication: 2021).Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Long lasting response to anti-tumor necrosis factor α agents in psoriasis: A real life experience.

Subjects: Adalimumab*/Adalimumab*/Adalimumab*/therapeutic use ; Etanercept*/Etanercept*/Etanercept*/therapeutic use ; Infliximab*/Infliximab*/Infliximab*/therapeutic use

  • Source: Dermatologic therapy [Dermatol Ther] 2022 Dec; Vol. 35 (12), pp. e15956. Date of Electronic Publication: 2022 Nov 01.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 9700070 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada.

  • Authors : Fenna J; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada, and Pharmacy Services, Alberta Health Services, Edmonton, Alberta, Canada.; McCormack D

Subjects: Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*therapeutic use ; Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/*therapeutic use ; Etanercept/Etanercept/Etanercept/*therapeutic use

  • Source: Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2021 Apr; Vol. 27 (4), pp. 444-452.Publisher: Academy of Managed Care Pharmacy Country of Publication: United States NLM ID: 101644425 Publication Model: Print Cited Medium: Internet

Record details

×
Academic Journal

Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.

  • Authors : Caporali R; Department of Clinical Sciences and Community Health, Research Centre for Adult and Pediatric Rheumatic Diseases, University of Milan, ASST Pini-CTO, Milan, Italy.; Allanore Y

Subjects: Adalimumab*/Adalimumab*/Adalimumab*/adverse effects ; Adalimumab*/Adalimumab*/Adalimumab*/therapeutic use ; Antirheumatic Agents*/Antirheumatic Agents*/Antirheumatic Agents*/administration & dosage

  • Source: Expert review of clinical immunology [Expert Rev Clin Immunol] 2021 Jan; Vol. 17 (1), pp. 85-99. Date of Electronic Publication: 2020 Dec 28.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101271248 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Long-term safety and efficacy of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis: a single center study.

  • Authors : Ricceri F; Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.; Rosi E

Subjects: Adalimumab*/Adalimumab*/Adalimumab*/adverse effects ; Adalimumab*/Adalimumab*/Adalimumab*/therapeutic use ; Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/adverse effects

  • Source: The Journal of dermatological treatment [J Dermatolog Treat] 2022 Jun; Vol. 33 (4), pp. 1983-1985. Date of Electronic Publication: 2022 Mar 23.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.

  • Authors : Mori A; The Shinko Institute for Medical Research, Shinko Hospital, Kobe, Japan.; Saito T

Subjects: Adalimumab/Adalimumab/Adalimumab/*immunology ; Antibodies/Antibodies/Antibodies/*immunology ; Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*immunology

  • Source: PloS one [PLoS One] 2020 Dec 14; Vol. 15 (12), pp. e0243729. Date of Electronic Publication: 2020 Dec 14 (Print Publication: 2020).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

×
Academic Journal

Assessment of Placental Disposition of Infliximab and Etanercept in Women With Autoimmune Diseases and in the Ex Vivo Perfused Placenta.

  • Authors : Eliesen GAM; Department of Pharmacology & Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.; van Drongelen J

Subjects: Autoimmune Diseases/Autoimmune Diseases/Autoimmune Diseases/*drug therapy ; Etanercept/Etanercept/Etanercept/*administration & dosage ; Infliximab/Infliximab/Infliximab/*administration & dosage

  • Source: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2020 Jul; Vol. 108 (1), pp. 99-106. Date of Electronic Publication: 2020 Apr 08.Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535

Record details

×
Editorial & Opinion

Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis.

  • Authors : Lund T; Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.; Sand C

Subjects: Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/*administration & dosage ; Etanercept/Etanercept/Etanercept/*administration & dosage ; Infliximab/Infliximab/Infliximab/*administration & dosage

  • Source: Dermatologic therapy [Dermatol Ther] 2019 May; Vol. 32 (3), pp. e12846. Date of Electronic Publication: 2019 Feb 22.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 9700070 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study.

  • Authors : Zhang K; Department of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.; National Translational Science Center for Molecular Medicine, Xi'an, China.

Subjects: Adalimumab/Adalimumab/Adalimumab/*therapeutic use ; Etanercept/Etanercept/Etanercept/*therapeutic use ; Hip/Hip/Hip/*pathology

  • Source: Frontiers in immunology [Front Immunol] 2021 Sep 29; Vol. 12, pp. 740980. Date of Electronic Publication: 2021 Sep 29 (Print Publication: 2021).Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet

Record details

×
Academic Journal

Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA).

  • Authors : Nassar-Sheikh Rashid A; Zaans Medical Center, Zaandam and Emma Children's Hospital, Amsterdam UMC, Pediatric Immunology, Rheumatology and Infectious Diseases, University of Amsterdam, Amsterdam, The Netherlands. .; Schonenberg-Meinema D

Subjects: Adalimumab*/Adalimumab*/Adalimumab*/immunology ; Adalimumab*/Adalimumab*/Adalimumab*/therapeutic use ; Arthritis, Juvenile*/Arthritis, Juvenile*/Arthritis, Juvenile*/drug therapy

  • Source: Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2021 Apr 29; Vol. 19 (1), pp. 59. Date of Electronic Publication: 2021 Apr 29.Publisher: BioMed Central Country of Publication: England NLM ID: 101248897 Publication Model: Electronic Cited Medium: Internet ISSN: 1546-0096

Record details

×
  • 1-10 of  3,427 results for ""INFLIXIMAB""